Figure 4. FK506 (tacrolimus) treatment
increases FK506 binding protein 51 (FKBP51) and nuclear factor
kappa-light-chain-enhancer of activated B (NF-kB) cell protein levels. A:
Twenty-four
hour FK506 treatments significantly increased protein
levels of FKBP51 and NF-κB in the 661w neuronal cell cultures. The 661w
neuronal cell cultures were treated for 24 h with a vehicle—100 nM
FK506, 1 μM FK506, or 10 μM FK506. Cell lysate proteins (25 µg) were
separated by sodium dodecyl sulfate PAGE (SDS–PAGE), transferred to
membranes, and immunoblotted for FKBP51, NF-κB, and glyceraldehyde
3-phosphate dehydrogenase (GAPDH). The quantification of band intensity
is represented as a percentage of FKBP51 or NF-κB of its corresponding
GAPDH control band on the same membrane. B: FK506 significantly
increased FKBP51 protein levels at a concentration of 10 μM (p=0.03),
while 0.1 μM and 1 μM caused an increased in FKBP51 protein levels;
however, significance was not obtained (n=3). Error bars represent SEM C:
Additionally,
FK506 significantly increased NF-κB protein levels at a
concentration of 0.1 μM (p=0.004), while 1 μM and 10 μM caused larger
increases in protein levels; however, significance was not obtained
(n=3 for each dose indicated).